ÂÜÀòÉç

Introduction

In 1989, Professor Gosling co-founded the anticancer drug discovery group at Newcastle that has become internationally recognised by virtue of its discoveries of inhibitors of numerous cancer-related targets, notably poly(ADP-ribose) polymerase (PARP-1). The PARP research led, in collaboration with Agouron Pharmaceuticals, to rucaparib (Rubraca), which recently acquired FDA and EMA approval for the treatment of BRCA-mutant ovarian cancer.

If you would like meet Professor Gosling please contact the seminar organiser.

Speakers

• Professor Bernard Gosling University of Newcastle, United Kingdom

---

Venue

University of Hull

Lecture Theatre C (third floor), Robert Blackburn Building (opp Chemistry), University of Hull, Cottingham Road, Hull, HU6 7RX, United Kingdom

Committee

• Phil Caygill Hull & East Yorkshire Local Section, United Kingdom

---

Organised by

Dr Andrew Boa, Senior Lecturer in Organic Chemistry, Chemistry & Biochemistry Department, University of Hull.

Contact information

Dr Andrew Boa
Contact us by email

---